What Eli Lilly's new employer platform could mean for access to weight-loss drugs

"By enabling coverage outside traditional benefit designs, we lower barriers to treatment and give employers greater control over how they support employee access to obesity care. This innovation can help employees access authentic obesity management medicines with more affordable out-of-pocket costs."

"Through this new employer platform, Lilly's Zepbound drug could be made available to employers for a discounted price of as little as $449 per month, which compares to its list price of more than $1,086. Zepbound was approved by the Food and Drug Administration in 2023 for chronic weight management."

Eli Lilly introduced a new program designed to help employers cover obesity medications more affordably, addressing what the company calls an "access gap" in U.S. obesity care. The initiative offers employers greater cost predictability and transparency while lowering employee out-of-pocket costs for obesity treatments. Through this platform, Lilly's Zepbound injectable can be provided at $449 per month, significantly below its list price of over $1,086. This move follows Lilly's earlier launch of LillyDirect, an online pharmacy for direct patient purchases. The program aims to give employers more control over supporting employee access to obesity management medicines while addressing widespread employer concerns about medication costs.

Read at Fast Company